Navigation Links
JCI early table of contents for May 15, 2013

Hot on the TRAIL of graft vs. host disease

For patients with leukemia and other hematological malignancies, transplantation of hematopoietic stem cells (HSCT) can be a powerfully effective therapy. In addition to the desirable anti-tumor effect, transplanted cells can also attack the host tissue, resulting in graft-versus-host disease (GVHD). In this issue of the Journal of Clinical Investigation, Arnab Ghosh and colleagues at Memorial Sloan-Kettering Cancer Center found that expression of a protein that causes cell death, TRAIL, in transplanted cells was critical for an effective anti-tumor response. Immune cells engineered to express higher levels of TRAIL killed the cells that cause GVHD and increased anti-tumor activity. In an accompanying commentary, Nelson Chao suggests that new therapeutics may take advantage of TRAIL-expressing cells to promote an anti-tumor response without putting patients at risk for GVHD.

TITLE: Fratricidal TRAIL+T cells suppress GVHD and augment anti-tumor activity after bone marrow transplantation

Arnab Ghosh
Memorial Sloan-Kettering Cancer Center, New York, , USA
Phone: 646-888-2317; E-mail:

View this article at:


TITLE: Blazing a new TRAIL in hematopoietic cell transplantation

Nelson J. Chao
Duke University Medical Center, Durham, NC, USA
Phone: 919-668-1011; Fax: 919-668-1091; E-mail:

View this article at:

Researchers identify signals that direct the immune system to reject a transplanted organ

Organ transplant rejection occurs when the transplant recipient's immune system identifies the transplanted organ as foreign tissue and attacks it. It was previously thought that T cells, the immune cells that mediate rejection, must first be activated by molecules known as chemokines in order to migrate to the transplanted organ. In this issue of the Journal of Clinical Investigation, Fadi Lakkis and colleagues at the University of Pittsburgh used mice to demonstrate that chemokine stimulation of T cells is not required for migration. Instead, these cells must come into contact with immune-stimulating proteins (antigens) that are specifically expressed by the transplanted organ. In an accompanying commentary, Terry Strom discusses how these findings could have important implications for the design of novel anti-rejection therapeutics.

TITLE: Cognate antigen directs CD8+ T cell migration to vascularized transplants

Fadi G. Lakkis
Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA
Phone: 412 383-5774; Fax: 412-383-9990; E-mail:

View this article at:


TITLE: Transplant rejection and paradigms lost

Terry Strom
Beth Israel Deaconess Medical Center, Boston, MA, USA
Phone: 1-617-735-2880; Fax: 1 617 667-0923; E-mail:

View this article at:


TITLE: Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium

George Kollias
Biomedical Sciences Research Centre (BSRC) "Alexander FLEMING", Institute o, Vari, GRC
Phone: 00302109656507; E-mail:

View this article at:

TITLE: Lamin B1 mediates cell-autonomous neuropathology in a leukodystrophy mouse model

Ying-Hui Fu
University of California San Francisco, San Francisco, CA, USA
Phone: 415-502-5614; E-mail:

View this article at:

TITLE: PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells

Rafi Ahmed
Emory University, Atlanta, GA, USA
Phone: 404-727-3571; E-mail:

View this article at:

TITLE: The genomic landscape of small intestine neuroendocrine tumors

Andreas Beutler
Mayo Clinic Rochester, Rochester, MN, USA
Phone: 507 2848009; E-mail:

View this article at:

TITLE: Specific peripheral B cell tolerance defects in patients with multiple sclerosis

Eric Meffre
Yale University School of Medicine, New Haven, CT, USA
Phone: 1-203-737-4535; Fax: 1-203-785-7903; E-mail:

View this article at:


Contact: Jillian Hurst
Journal of Clinical Investigation

Related medicine news :

1. Nearly 50 percent increase in ICU admissions, new study says
2. The search for an early biomarker to fight atherosclerosis
3. Nearly Half of High Schoolers Text While Driving: Survey
4. iPads Could Affect Implanted Heart Devices, Early Study Finds
5. Wireless Pacemaker Shows Promise in Early Study
6. JCI early table of contents for May 8, 2013
7. Study finds nearly 5 million asthmatics worldwide could benefit from antifungal therapy
8. Children and Teens in Emergency Departments Who Are at Risk for Suicide: Nearly 20% Have Access to Guns
9. Living Long May Protect Against Early Alzheimers, Study Finds
10. Hospitals Enact Policies to Curb Early Childbirth
11. Nearly 20 percent of suicidal youths have guns in their home
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at ... people age, more care is needed, especially with Alzheimer’s, dementia and other cognitive ... being overworked. The forgotten part of this equation: 80 percent of medical care ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... 2015 , ... "When I was traveling, I was very ... "Many people catch diseases simply from sitting on such dirty toilet seats. I ... germs." , He developed the patent-pending QUDRATECS to eliminate the need to sit ...
(Date:11/27/2015)... County, CA (PRWEB) , ... November 27, 2015 , ... ... season , The company is offering customers 10% off of their purchase of lice ... any treatment at full price. According to a company spokesperson. “Finding lice is a ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Pays-Bas, November 27, 2015 ... au traitement photodynamique au Bremachlorin contre le cancer ... approche consistant à combiner l,immunothérapie au traitement photodynamique ... --> Une nouvelle approche consistant ... contre le cancer avancé.    ...
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... Ein neuer Kombinationsansatz vereint ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... Clinical Cancer Research vom 6. November ... vom 6. November 2015 berichtet. --> ...
Breaking Medicine Technology: